Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Turkish Hospitals' Billion-Dollar Debt A Top Priority For Medtech Suppliers

Executive Summary

While many medtech companies are looking at strategies to grow their sales this new year, those that are operating in Turkey look like their focus would be on simply getting paid for what is owed by the country's debt-ridden hospitals.

You may also be interested in...



Turkish Government Steps In To Pay Off Longstanding Debt

Turkey's financially beleaguered university hospitals can finally breathe a sigh of relief after the Turkish government has agreed to step in to help pay off most – not all – of the billion-dollar debt owed to the medtech industry.

Turkey Sets Wave Of Reimbursement Hikes Across 160-Plus Medical Products

Turkey's public health care payor has increased reimbursement prices of over 160 medical devices, the first time in almost 10 years. It has also eased the reimbursement process for patients to increase their access to medical products.

Could The City Hospitals Project Be A Bit Of A Turkey?

As Turkey’s City Hospitals project goes underway, with the first few hospitals already up and running, big medtech players are swooping down to capitalize on this opportunity which promise to boost the Turkish market by up to TRY2bn. However, intense competition, as well as basic problems that had been plaguing companies operating in that country, persists and still needs to be resolved.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT104301

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel